Detalles de la búsqueda
1.
A phase 1b study evaluating the effect of elacestrant treatment on estrogen receptor availability and estradiol binding to the estrogen receptor in metastatic breast cancer lesions using 18F-FES PET/CT imaging.
Breast Cancer Res
; 22(1): 97, 2020 09 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-32912274
2.
EMERALD: Phase III trial of elacestrant (RAD1901) vs endocrine therapy for previously treated ER+ advanced breast cancer.
Future Oncol
; 15(28): 3209-3218, 2019 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-31426673
3.
Factors influencing long-term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib.
Br J Haematol
; 172(1): 97-110, 2016 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-26537529
4.
A Phase II Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma.
Clin Cancer Res
; 29(22): 4555-4563, 2023 11 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-37643133
5.
Phase I dose-escalation and pharmacokinetic study of ispinesib, a kinesin spindle protein inhibitor, administered on days 1 and 15 of a 28-day schedule in patients with no prior treatment for advanced breast cancer.
Anticancer Drugs
; 23(3): 335-41, 2012 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-22123335
6.
A First-in-Human Phase 1 Study of a Novel Selective Androgen Receptor Modulator (SARM), RAD140, in ER+/HER2- Metastatic Breast Cancer.
Clin Breast Cancer
; 22(1): 67-77, 2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34565686
7.
Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial.
J Clin Oncol
; 40(28): 3246-3256, 2022 10 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35584336
8.
Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer.
J Clin Oncol
; 39(12): 1360-1370, 2021 04 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-33513026
9.
A pediatric phase I trial and pharmacokinetic study of ispinesib: a Children's Oncology Group phase I consortium study.
Pediatr Blood Cancer
; 55(7): 1323-8, 2010 Dec 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-20712019
10.
Pharmacokinetic and Pharmacodynamic Studies of Elacestrant, A Novel Oral Selective Estrogen Receptor Degrader, in Healthy Post-Menopausal Women.
Eur J Drug Metab Pharmacokinet
; 45(5): 675-689, 2020 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-32661909
11.
Correction to: Pharmacokinetic and Pharmacodynamic Studies of Elacestrant, A Novel Oral Selective Estrogen Receptor Degrader, in Healthy Post-Menopausal Women.
Eur J Drug Metab Pharmacokinet
; 45(5): 691-692, 2020 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-32862369
12.
The role of photochemical treatment with amotosalen and UV-A light in the prevention of transfusion-transmitted cytomegalovirus infections.
Transfus Med Rev
; 20(1): 45-56, 2006 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-16373187
13.
Platelets photochemically treated with amotosalen HCl and ultraviolet A light correct prolonged bleeding times in patients with thrombocytopenia.
Transfusion
; 46(5): 731-40, 2006 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-16686840
14.
Platelet dose consistency and its effect on the number of platelet transfusions for support of thrombocytopenia: an analysis of the SPRINT trial of platelets photochemically treated with amotosalen HCl and ultraviolet A light.
Transfusion
; 46(1): 24-33, 2006 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-16398727
15.
Pathogen inactivation of platelets with a photochemical treatment with amotosalen HCl and ultraviolet light: process used in the SPRINT trial.
Transfusion
; 46(4): 562-71, 2006 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-16584432
16.
Transfusion of 7-day-old amotosalen photochemically treated buffy-coat platelets to patients with thrombocytopenia: a pilot study.
Transfusion
; 46(3): 424-33, 2006 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-16533286
17.
A randomized, controlled Phase III trial of therapeutic plasma exchange with fresh-frozen plasma (FFP) prepared with amotosalen and ultraviolet A light compared to untreated FFP in thrombotic thrombocytopenic purpura.
Transfusion
; 46(10): 1693-704, 2006 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-17002625
18.
Amotosalen interactions with platelet and plasma components: absence of neoantigen formation after photochemical treatment.
Transfusion
; 45(10): 1610-20, 2005 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-16181212
19.
Clinical safety of platelets photochemically treated with amotosalen HCl and ultraviolet A light for pathogen inactivation: the SPRINT trial.
Transfusion
; 45(12): 1864-75, 2005 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-16371039
20.
Therapeutic efficacy and safety of red blood cells treated with a chemical process (S-303) for pathogen inactivation: a Phase III clinical trial in cardiac surgery patients.
Transfusion
; 45(11): 1739-49, 2005 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-16271099